Unite with Fellow Investors
Choose the Best Attorney
Follow Case Progress
id: 730, Created by Stan Vick Chase, Scout
Enzo Biochem (ENZ) Asset Sale Case
What do I get by joining?
- You will get case updates and receive a payout in case of success
- If you would like to actively participate, you will be connected to the attorney
- No, you do not pay anything out of your pocket neither to us nor to attorney
On March 16, 2023, Enzo Biochem, Inc. (NYSE: ENZ) announced that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo’s Clinical Laboratory division (Enzo Clinical Labs).
In 2022, Enzo Biochem initiated a strategic initiative to restructure operations to target business areas and industry sectors representing major growth opportunities.
Investors may have reasons to suspect $ENZ, its Leaders, and its Advisors of failing to act in the best interests of shareholders.
Failure to Disclose,
Breach of Fiduciary duty,
Shock Event Date
16 March 2023